GleamWall
中文EN

ALZN Alzamend Neuro, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1677077 · Fiscal year ends 04/30

Financial factors as of 2026-07-31 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-45.7%
TTM EPS YoY-72.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-163.2%
ROA-122.4%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets32.1%
Debt / equity0.00x
Current ratio—
Interest coverage-1,480.55x

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-30.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20262026-04-30FY20252025-04-30
Income statement
Revenue——
R&D expense$3.63M$1.41M
SG&A expense$5.14M$3.08M
Operating income-$8.77M-$4.50M
Interest expense$6,619$18,029
Pretax income-$8.77M-$4.51M
Net income-$8.77M-$4.51M
EBITDA-$8.66M-$4.45M
EPS (basic)-2.63-11.32
EPS (diluted)-2.63-11.32
Weighted avg. shares (diluted)3.34M450,799
Balance sheet
Cash & equivalents$710,689$3.95M
Current assets$1.76M$4.18M
PP&E, net$314,866$425,606
Total assets$2.08M$4.60M
Total liabilities$1.35M$634,761
Shareholders' equity$733,211$3.97M
Shares outstanding4.26M778,733
Cash flow statement
Operating cash flow-$8.07M-$6.57M
Investing cash flow—-$300,000
Financing cash flow$4.83M$10.44M
Depreciation & amortization$110,740$50,740
Stock-based compensation$707,527$325,108

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.